Research ExplorerPublicationsIncidence of abacavir hypersensitivity reactions in euroSIDA...

Incidence of abacavir hypersensitivity reactions in euroSIDA.

Standard

Incidence of abacavir hypersensitivity reactions in euroSIDA. / Bannister, Wendy P; Friis-Møller, Nina; Mocroft, Amanda; Viard, Jean-Paul; van Lunzen, Jan; Kirk, Ole; Gargalianos, Panagiotis; Bánhegyi, Dénes; Chiesi, Antonio; Lundgren, Jens D.

In: ANTIVIR THER, Vol. 13, No. 5, 5, 2008, p. 687-696.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bannister, WP, Friis-Møller, N, Mocroft, A, Viard, J-P, van Lunzen, J, Kirk, O, Gargalianos, P, Bánhegyi, D, Chiesi, A & Lundgren, JD 2008, 'Incidence of abacavir hypersensitivity reactions in euroSIDA.', ANTIVIR THER, vol. 13, no. 5, 5, pp. 687-696. <http://www.ncbi.nlm.nih.gov/pubmed/18771052?dopt=Citation>

APA

Bannister, W. P., Friis-Møller, N., Mocroft, A., Viard, J-P., van Lunzen, J., Kirk, O., Gargalianos, P., Bánhegyi, D., Chiesi, A., & Lundgren, J. D. (2008). Incidence of abacavir hypersensitivity reactions in euroSIDA. ANTIVIR THER, 13(5), 687-696. [5]. http://www.ncbi.nlm.nih.gov/pubmed/18771052?dopt=Citation

Vancouver

Bannister WP, Friis-Møller N, Mocroft A, Viard J-P, van Lunzen J, Kirk O et al. Incidence of abacavir hypersensitivity reactions in euroSIDA. ANTIVIR THER. 2008;13(5):687-696. 5.

Bibtex

@article{bbc1e8af67c940fa9124876450919b0e,
title = "Incidence of abacavir hypersensitivity reactions in euroSIDA.",
abstract = "BACKGROUND: The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients. METHODS: Poisson regression models were developed to compare incidence of abacavir discontinuation according to the line of therapy within which abacavir was received, geographical regions, calendar time and drug formulation (abacavir/lamivudine combination tablet versus abacavir as a single drug or abacavir/zidovudine/lamivudine combination). RESULTS: Of 3,278 patients that started abacavir, 2,101 (64.1%) discontinued. Of these, 167 (5.1%) discontinued abacavir within 3 months due to HSR with an incidence of 22.1 (95% confidence interval [CI] 18.7-25.4) per 100 person-years of follow-up. After adjustment for gender, prior AIDS, hepatitis C serostatus, baseline CD4+ T-cell count, region and calendar time, HSR incidence was significantly higher in those starting abacavir in a first-line regimen compared with second-line (incidence rate ratio [IRR] 2.04 [95% CI 1.24-3.38]; P=0.005). There was no significant difference between regions. HSR incidence from 2005 onwards was significantly lower compared with 1999-2000 (IRR 0.54 [95% CI 0.32-0.92]; P=0.024). There was a lower observed incidence in patients starting abacavir/lamivudine compared with other formulations (IRR 0.33 [95% CI 0.13-0.88]; P=0.027), however, available data were limited. CONCLUSIONS: Incidence of abacavir-related HSR is higher in patients starting abacavir in first-line therapy, which could indicate increased over-diagnosis. HSR incidence has decreased in recent years, which might reflect the wider availability of genetic screening and improved awareness of symptoms. There were no reported deaths due to abacavir HSR.",
author = "Bannister, {Wendy P} and Nina Friis-M{\o}ller and Amanda Mocroft and Jean-Paul Viard and {van Lunzen}, Jan and Ole Kirk and Panagiotis Gargalianos and D{\'e}nes B{\'a}nhegyi and Antonio Chiesi and Lundgren, {Jens D}",
year = "2008",
language = "Deutsch",
volume = "13",
pages = "687--696",
journal = "ANTIVIR THER",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - Incidence of abacavir hypersensitivity reactions in euroSIDA.

AU - Bannister, Wendy P

AU - Friis-Møller, Nina

AU - Mocroft, Amanda

AU - Viard, Jean-Paul

AU - van Lunzen, Jan

AU - Kirk, Ole

AU - Gargalianos, Panagiotis

AU - Bánhegyi, Dénes

AU - Chiesi, Antonio

AU - Lundgren, Jens D

PY - 2008

Y1 - 2008

N2 - BACKGROUND: The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients. METHODS: Poisson regression models were developed to compare incidence of abacavir discontinuation according to the line of therapy within which abacavir was received, geographical regions, calendar time and drug formulation (abacavir/lamivudine combination tablet versus abacavir as a single drug or abacavir/zidovudine/lamivudine combination). RESULTS: Of 3,278 patients that started abacavir, 2,101 (64.1%) discontinued. Of these, 167 (5.1%) discontinued abacavir within 3 months due to HSR with an incidence of 22.1 (95% confidence interval [CI] 18.7-25.4) per 100 person-years of follow-up. After adjustment for gender, prior AIDS, hepatitis C serostatus, baseline CD4+ T-cell count, region and calendar time, HSR incidence was significantly higher in those starting abacavir in a first-line regimen compared with second-line (incidence rate ratio [IRR] 2.04 [95% CI 1.24-3.38]; P=0.005). There was no significant difference between regions. HSR incidence from 2005 onwards was significantly lower compared with 1999-2000 (IRR 0.54 [95% CI 0.32-0.92]; P=0.024). There was a lower observed incidence in patients starting abacavir/lamivudine compared with other formulations (IRR 0.33 [95% CI 0.13-0.88]; P=0.027), however, available data were limited. CONCLUSIONS: Incidence of abacavir-related HSR is higher in patients starting abacavir in first-line therapy, which could indicate increased over-diagnosis. HSR incidence has decreased in recent years, which might reflect the wider availability of genetic screening and improved awareness of symptoms. There were no reported deaths due to abacavir HSR.

AB - BACKGROUND: The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients. METHODS: Poisson regression models were developed to compare incidence of abacavir discontinuation according to the line of therapy within which abacavir was received, geographical regions, calendar time and drug formulation (abacavir/lamivudine combination tablet versus abacavir as a single drug or abacavir/zidovudine/lamivudine combination). RESULTS: Of 3,278 patients that started abacavir, 2,101 (64.1%) discontinued. Of these, 167 (5.1%) discontinued abacavir within 3 months due to HSR with an incidence of 22.1 (95% confidence interval [CI] 18.7-25.4) per 100 person-years of follow-up. After adjustment for gender, prior AIDS, hepatitis C serostatus, baseline CD4+ T-cell count, region and calendar time, HSR incidence was significantly higher in those starting abacavir in a first-line regimen compared with second-line (incidence rate ratio [IRR] 2.04 [95% CI 1.24-3.38]; P=0.005). There was no significant difference between regions. HSR incidence from 2005 onwards was significantly lower compared with 1999-2000 (IRR 0.54 [95% CI 0.32-0.92]; P=0.024). There was a lower observed incidence in patients starting abacavir/lamivudine compared with other formulations (IRR 0.33 [95% CI 0.13-0.88]; P=0.027), however, available data were limited. CONCLUSIONS: Incidence of abacavir-related HSR is higher in patients starting abacavir in first-line therapy, which could indicate increased over-diagnosis. HSR incidence has decreased in recent years, which might reflect the wider availability of genetic screening and improved awareness of symptoms. There were no reported deaths due to abacavir HSR.

M3 - SCORING: Zeitschriftenaufsatz

VL - 13

SP - 687

EP - 696

JO - ANTIVIR THER

JF - ANTIVIR THER

SN - 1359-6535

IS - 5

M1 - 5

ER -